[The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000188:drug therapy; D010919:Placebos
D010276:Parasympatholytics; D010919:Placebos; D000547:Amantadine
Terapevticheskaia effektivnost' amantadina (midantana) pri sindromakh parkinsonizma.